Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|October 11, 2012
Study: Tranexamic acid reduces bleeding deaths, thrombotic events in all trauma patients
Tranexamic acid can safely be used in all trauma patients, not just those who are the most severely injured, according to data analyses results published in the Sept. 11 issue of the British Medical Journal.
Advertisement
Advertisement
Related to this article
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
3
Expert Discusses Flu and COVID-19 Vaccine Guidance
4
Nicotine Pouches Create Opportunity for Pharmacist Counseling
5